BACKGROUND: Autologous vein grafts and balloon angioplasty are still commonly used for arterial reconstructive procedures. Their success is limited by the development of intimal hyperplasia (IH). Biliverdin (BVD), one of the by-products of heme degradation, has been shown to have potent antioxidant and antiinflammatory effects. We hypothesized that BVD administration would protect vascular tissue against vascular injury. METHODS AND RESULTS: The effects of BVD administration against IH after vascular injury were analyzed in an arterialized vein graft model and a balloon injury model in rats. BVD treatment significantly suppressed the development of IH in both models compared with those without BVD. The mechanisms by which BVD treatment inhibits IH development might include decreasing c-Jun NH2 terminal kinase activation and preventing apoptosis of endothelial cells. BVD also suppressed vascular smooth muscle cell migration in vitro. CONCLUSIONS: BVD administration prevented IH associated with arterialized vein graft vasculopathy or balloon angioplasty-induced vessel injury. These results suggest that a treatment regimen with exogenous BVD administration could provide an effective therapeutic adjunct to facilitate transfer of experimental treatments for vascular injury to the clinic.
BACKGROUND: Autologous vein grafts and balloon angioplasty are still commonly used for arterial reconstructive procedures. Their success is limited by the development of intimal hyperplasia (IH). Biliverdin (BVD), one of the by-products of heme degradation, has been shown to have potent antioxidant and antiinflammatory effects. We hypothesized that BVD administration would protect vascular tissue against vascular injury. METHODS AND RESULTS: The effects of BVD administration against IH after vascular injury were analyzed in an arterialized vein graft model and a balloon injury model in rats. BVD treatment significantly suppressed the development of IH in both models compared with those without BVD. The mechanisms by which BVD treatment inhibits IH development might include decreasing c-Jun NH2 terminal kinase activation and preventing apoptosis of endothelial cells. BVD also suppressed vascular smooth muscle cell migration in vitro. CONCLUSIONS:BVD administration prevented IH associated with arterialized vein graft vasculopathy or balloon angioplasty-induced vessel injury. These results suggest that a treatment regimen with exogenous BVD administration could provide an effective therapeutic adjunct to facilitate transfer of experimental treatments for vascular injury to the clinic.
Authors: Qiang Sun; Tomohiro Kawamura; Kosuke Masutani; Ximei Peng; Qing Sun; Donna B Stolz; John P Pribis; Timothy R Billiar; Xuejun Sun; Christian A Bermudez; Yoshiya Toyoda; Atsunori Nakao Journal: Cardiovasc Res Date: 2012-01-27 Impact factor: 10.787
Authors: Atsunori Nakao; Chien-Sheng Huang; Donna B Stolz; Yinna Wang; Jonathan M Franks; Naobumi Tochigi; Timothy R Billiar; Yoshiya Toyoda; Edith Tzeng; Kenneth R McCurry Journal: Cardiovasc Res Date: 2010-09-16 Impact factor: 10.787
Authors: Miguel Zabalgoitia; James T Colston; Seenu V Reddy; Jeffrey W Holt; Raymond F Regan; David E Stec; John M Rimoldi; Anthony J Valente; Bysani Chandrasekar Journal: Free Radic Biol Med Date: 2007-08-24 Impact factor: 7.376
Authors: Andres I Rodriguez; Archana Gangopadhyay; Eric E Kelley; Patrick J Pagano; Brian S Zuckerbraun; Philip M Bauer Journal: Arterioscler Thromb Vasc Biol Date: 2009-10-29 Impact factor: 8.311